The purpose of this study is to help clarify the discrepancies in the literature and determine whether abnormal CEA levels may be used as a tumor marker to predict the severity of disease in MTC in regards to size of tumor, stage of tumor, lymph node involvement, distant metastasis, surgical cure, and mortality. The gene discussed is CEACAM5; the disease is neoplasm.